CDMOs/CMOs: The Key Moves in 2026
What have been key moves—capacity additions and acquisitions by CDMOs of drug substances (small molecules and biologics) thus far in 2026? A roundup of key developments.
Patricia Van Arnum
The CDMO/CMO Report
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
EU Energy and Supply: What Will Happen Next?
The European Commission proposed last month an emergency intervention in Europe’s energy markets to address recent dramatic price rises as the EU faces the effects of a severe mismatch between energy demand and supply. What is in the proposal?
Ramping Up Biomanufacturing Capacity
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.
Opportunities in Drug Development and Manufacturing
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
